ABOUT THIS PROSPECTUS SUPPLEMENT
This prospectus supplement and the accompanying prospectus dated May 24, 2022, are part of an automatic registration statement that we filed with the
Securities and Exchange Commission, or the SEC, as a well-known seasoned issuer as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act, using a shelf registration process. Under this shelf
registration process, we may from time to time sell any combination of the securities described in this prospectus supplement in one or more offerings. Under this prospectus supplement, we may from time to time sell shares of our common stock having
an aggregate offering price of up to $150,000,000, at prices and on terms to be determined by market conditions at the time of the offering.
This
prospectus supplement describes the terms of this offering of common stock and also adds to and updates information contained in the documents incorporated by reference into this prospectus supplement. To the extent there is a conflict between the
information contained in this prospectus supplement, on the one hand, and the information contained in any document incorporated by reference into this prospectus supplement that was filed with the SEC before the date of this prospectus supplement,
on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later datefor example, a document incorporated by
reference into this prospectus supplementthe statement in the document having the later date modifies or supersedes the earlier statement.
We have
not, and the Sales Agents have not, authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus supplement, the accompanying base prospectus supplement or any related free writing
prospectus to which we have referred you. Neither we nor the Sales Agents take any responsibility for, and can provide no assurance as to the reliability of, any other information others may give you. We are not, and the Sales Agents are not,
making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or
solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying base prospectus, the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for
use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus
supplement, the accompanying base prospectus, the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment
decision.
When we refer to Chinook, Chinook Therapeutics, we, our, us, the
Registrant, the Company and our company in this prospectus supplement, we mean Chinook Therapeutics, Inc., a Delaware corporation, unless otherwise specified.
The mark Chinook Therapeutics, Inc., the Chinook Therapeutics logo and all product candidate names are our common law trademarks. All other
service marks, trademarks and tradenames appearing in this prospectus supplement are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this prospectus supplement appear without the ® and symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest
extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.
S-ii